VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The characteristics of patients with myelofibrosis taking ruxolitinib for 3 or more years

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the clinical characteristics of patients with myelofibrosis (MF) taking ruxolitinib for three or more years. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter